Sort   by:  
 Page size 
UnknownEfficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial.
Not available
S-EPMC8711034 | biostudies-literature
UnknownCost-Utility Analysis of Accelerated and Standard Strategies for Renal Replacement Therapy Initiation.
Not available
S-EPMC12495491 | biostudies-literature
UnknownStratified analyses refine association between TLR7 rare variants and severe COVID-19.
Not available
S-EPMC11320601 | biostudies-literature
UnknownRegional Practice Variation and Outcomes in the Standard Versus Accelerated Initiation of Renal Replacement Therapy in Acute Kidney Injury (STARRT-AKI) Trial: A Post Hoc Secondary Analysis.
Not available
S-EPMC10878545 | biostudies-literature
UnknownA Bayesian reanalysis of the Standard versus Accelerated Initiation of Renal-Replacement Therapy in Acute Kidney Injury (STARRT-AKI) trial.
Not available
S-EPMC9404618 | biostudies-literature
UnknownFactors associated with adverse haemodynamic events during the STARRT-AKI trial: a post-hoc secondary analysis.
Not available
S-EPMC12751851 | biostudies-literature
UnknownWhole-genome sequencing reveals host factors underlying critical COVID-19.
Not available
S-EPMC9259496 | biostudies-literature
Sort   by:  
 Page size